Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending May 15, 2012. The report details a specific share repurchase transaction executed in accordance with shareholder authority granted at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 1,400,000 Ordinary shares of 25 pence each.
- Purchase Date: May 15, 2012.
- Price Range: Highest price paid was 1,425 pence per share; lowest price paid was 1,416.5 pence per share.
- Treasury Holdings (Settled): 528,147,927 shares (9.49% of total issued share capital).
- Treasury Holdings (Including Unsettled): 531,747,927 shares (10.56% of current total voting rights).
- Shares in Issue (Excluding Treasury): 5,036,441,321 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 1,400,000 shares for Treasury. Consequently, the percentage of shares held in Treasury increased to 9.49% of issued capital and 10.56% of total voting rights when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Investor Verification Checklist
- Verify the total number of shares in issue (5,036,441,321) for calculating disclosure thresholds under Financial Services Authority rules.
- Confirm the current percentage of voting rights held in Treasury (10.56% including unsettled shares).
- Review the specific price range paid (1,416.5 to 1,425 pence) against market prices on May 15, 2012.
- Check subsequent filings for the settlement status of the 1,400,000 shares purchased.